Overexpression of the chromatin remodeler Znhit1 alleviated migraine-like pain in mice by reducing CGRP expression, increasing serotonin, and suppressing NLRP3 inflammasome-driven inflammation.
CGRP and NLRP3 both suppressedZnhit1 overexpression reduced CGRP (the primary migraine neuropeptide) and blocked NLRP3 inflammasome activation simultaneously, connecting migraine biology to the inflammasome pathway and suggesting NLRP3 inhibitors as potential migraine therapeutics.
What the researchers found
In a nitroglycerin-induced migraine mouse model:
- Znhit1 expression was reduced in the trigeminal nucleus caudalis (TNC) — the brain's migraine pain center
- Overexpression of Znhit1 produced multiple beneficial effects:
- Alleviated thermal and mechanical hyperalgesia (pain hypersensitivity)
- Upregulated 5-HT (serotonin) levels
- Inhibited c-Fos expression (a marker of neuronal activation)
- Reduced CGRP expression (the key migraine neuropeptide)
- Downregulated inflammatory markers: IL-6, IL-1β, TNF-α, COX-2, iNOS
- Inhibited NLRP3 inflammasome activation
In vitro: Znhit1 silencing in microglia enhanced inflammation and apoptosis via NLRP3 activation, which was reversed by the specific NLRP3 inhibitor MCC950 — confirming NLRP3 as the key downstream target.
Why it matters
CGRP-targeting drugs (anti-CGRP antibodies and gepant antagonists) have revolutionized migraine treatment but don't work for everyone. Understanding what naturally regulates CGRP expression could reveal new therapeutic targets. Znhit1 represents a novel upstream regulator of CGRP that operates through the NLRP3 inflammasome pathway. This connects migraine biology to the broader field of inflammasome-mediated diseases and could open new treatment avenues, including the potential use of existing NLRP3 inhibitors for migraine.
How the study worked
A chronic migraine mouse model was established by repeated intraperitoneal nitroglycerin injection. Znhit1 expression was measured by qPCR and western blot. Pain was assessed by Von Frey monofilaments (mechanical) and hot plate assay (thermal). Inflammatory markers were measured by ELISA and western blot. Molecular mechanisms were explored in vitro using BV2 microglial cells with Znhit1 overexpression or silencing, LPS stimulation, and the NLRP3 inhibitor MCC950.
What this study cannot tell us
This is a preclinical mouse study — the nitroglycerin migraine model captures some aspects of human migraine but not all. Znhit1 overexpression was achieved by viral vector injection, which is not a practical therapeutic approach. The relationship between Znhit1 levels and human migraine has not been established. The specific cell types expressing Znhit1 in the TNC are not fully characterized. In vitro experiments used LPS-stimulated microglia, which may not perfectly model migraine-associated inflammation.
How to read the evidence
This is a preclinical mouse study combining in vivo migraine modeling with in vitro mechanistic experiments. While it identifies a novel regulatory pathway (Znhit1 → NLRP3 → CGRP), the findings are from animal and cell models and require validation in human migraine patients.
When this study was published
Published in 2025, this is a very recent study contributing new mechanistic insights to the rapidly evolving understanding of CGRP regulation and inflammasome involvement in migraine.
The bigger picture
The discovery that Znhit1 regulates CGRP expression through the NLRP3 inflammasome adds a new layer to migraine neurobiology. NLRP3 inflammasome activation has been implicated in Alzheimer's, atherosclerosis, and type 2 diabetes — and NLRP3 inhibitors are in clinical development. This study suggests they might also have a role in migraine prevention, potentially expanding the therapeutic toolkit beyond CGRP-specific drugs. The chromatin-remodeling connection also raises the possibility that epigenetic mechanisms contribute to migraine susceptibility.
Questions still open
- Are Znhit1 levels reduced in the trigeminal system of human migraine patients?
- Could NLRP3 inflammasome inhibitors like MCC950 or dapansutrile be repurposed as migraine preventive therapies?
- Does Znhit1 regulate CGRP expression directly through chromatin remodeling at the CGRP gene locus, or indirectly through inflammatory pathways?
Common questions
What is the connection between CGRP and migraine?
Could inflammasome inhibitors become migraine treatments?
Read the original research
Znhit1 alleviates nitroglycerin-induced hyperalgesia in migraine mice via the inhibition of NOD-like receptor signaling pathway.
Molecular pain, 21, 17448069251389420
Citation
Wang, Xue; Tang, Jianhua; Hou, Yiwei; Sui, Changbai. (2025). Znhit1 alleviates nitroglycerin-induced hyperalgesia in migraine mice via the inhibition of NOD-like receptor signaling pathway.. Molecular pain, 21, 17448069251389420. https://doi.org/10.1177/17448069251389420